Genmab A/S's Form 4 filing
Merus N.V. (MRUS) · filed Dec 29, 2025
- Accession no.
- 0001193125-25-335521
- Filed
- Dec 29, 2025
- Trade date
- Dec 22-26, 2025
- Filing delay
- 7 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $79.1M. It was filed 7 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Genmab A/SCIK 0001434265 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseAcquired | +15,710 | $97.00 | +$1,523,870 | 72,028,775 | Indirect | |
| Dec 23, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseAcquired | +561,042 | $97.00 | +$54,421,074 | 72,589,817 | Indirect | |
| Dec 24, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseAcquired | +96,082 | $97.00 | +$9,319,954 | 72,685,899 | Indirect | |
| Dec 26, 2025 | Common Shares, nominal value EUR 0.09 per share | PPurchaseAcquired | +142,610 | $97.00 | +$13,833,170 | 72,828,509 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.